<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Med Insights Circ Respir Pulm Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Med Insights Circ Respir Pulm Med</journal-id><journal-title-group><journal-title>Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine</journal-title></journal-title-group><issn pub-type="epub">1179-5484</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3425328</article-id><article-id pub-id-type="doi">10.4137/CCRPM.S10348</article-id><article-id pub-id-type="publisher-id">ccrpm-6-2012-051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum for &#x0201c;Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations&#x0201d;</article-title></title-group><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>13</day><month>8</month><year>2012</year></pub-date><volume>6</volume><fpage>51</fpage><lpage>51</lpage><permissions><copyright-statement>&#x000a9; the author(s), publisher and licensee Libertas Academica Ltd.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p>Stephen K. Field</p><p>Division of Respiratory Medicine, University of Calgary, Calgary, Alberta, Canada.</p><p>This correction concerns <related-article related-article-type="corrected-article" id="d34e56" vol="5" page="57" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="22084617" ext-link-type="pubmed">Stephen K. Field, Roflumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 2011;5:57&#x02013;70.</related-article></p><p>The full citation for the new version is: Stephen K. Field. Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 2011;5:57&#x02013;70.</p><p>Corrections</p><p>1. Page 63, left column, 2nd sentence in the first paragraph: It is a selective not a nonselective PDE4i.</p><p>2. Page 63, left column, 1st paragraph of &#x02018;Pharmacology of roflumilast&#x02019;, 10th to 12 lines, should read: times to peak concentration are 0.9 and 4 hours and elimination half lives are 16 and 21 hours.</p><p>3. Page 64, right column, 3rd line from the top, 14% not 13% reduction.</p><p>4. Page 65, left column, last sentence of the first paragraph, the median time to the first AECOPD was greater not less in the roflumilast treated patients.</p><p>5. Page 66, right column, last sentence of the first paragraph in the summary, reference should be 76 not 75.</p><p>6. Page 67, table 6, last 2 rows of far right column, numbers are reversed, should be 1.9 vs. 2.4 and 1.8 vs. 2.2.</p></body></article>